// App-Quantinova.ai

SU-OR33 : Prognostic Value of Persistent Proteinuria and Hematuria After Induction Therapy in ANCA-Associated Vasculitides

Researchers

Presenter

  • Benichou Nicolas

Principal Investigators

  • Guillevin Loc

  • Charles Pierre

  • Terrier Benjamin

  • Mouthon Luc

  • Hiemstra ThomasF

  • Jones RachelB

  • Jayne DavidR.W

  • Karras Alexandre

Medical Centers

  • Hôpital Européen Georges Pompidou, Paris, Ile-de-France, France

  • Hopital Tenon Paris Île-de-France France

  • Institut Mutualiste Montsouris Paris Île-de-France France

  • Addenbrooke's Hospital Cambridge Cambridgeshire United Kingdom

Locations

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • End stage renal disease

  • Albuminuria

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved